[ad_1]
– Advertising –
SINGAPORE – Singapore could possibly have a Covid-19 vaccine early next year.
A report in The Straits Times explained that the preliminary shipment of the vaccine, which was developed jointly with researchers from Singapore, is scheduled for the first quarter of 2021.
The American pharmaceutical company, Arcturus Therapeutics, has been collaborating with Duke-NUS scientists on the vaccine, and the company made an announcement on Monday (November 9) that its early-stage clinical trials have had positive results so far.
Along with this news, the pharmaceutical company also shared that the Singapore Economic Development Board (EDB) is releasing S $ 60.5 million to complete the vaccine. They also said that EDB will have the option to purchase vaccines at pre-negotiated prices of up to $ 175 million.
– Advertising –
The vaccine’s co-developer, Duke-NUS School of Medicine professor Ooi Eng Eong, also shared that it appears that a single dose may already prove effective.
Professor Eong, who is also on the Scientific Advisory Board of the Arcturus Vaccine Platform, explained that “this differentiates this investigational vaccine from many other Covid-19 vaccines in development.”
“The vaccine has the potential to provide important public health benefits by greatly facilitating broad administration in multiple populations around the world,” he added.
According to Andy Sassine, Chief Financial Officer of Arcturus, the Singapore funding will increase the company’s resources to sustain the rapid roll-out of the vaccine. This is also so that the pharmaceutical company can maintain its current agreements with Israel and Singapore, as well as other possible supply agreements that could occur in 2021.
This is not the only vaccine you are finding that your preliminary studies are showing more promise. Pfizer and BioNTech have also announced that they are also preparing a 90% effective vaccine.
How to share in a straitstimes.com In the report, Pfizer CEO and Chairman Albert Bourla said: “The first set of results from our Phase 3 Covid-19 vaccine trial provides initial evidence of our vaccine’s ability to prevent Covid-19. “.
As for the Arcturus trials conducted in Singapore, about 106 volunteers were enrolled in trials with 28 subjects who received placebos. Additionally, 78 volunteers received one dose of the vaccine, while the remaining subjects received two injections.
Researchers have been on the lookout for negative side effects in patients, but so far, the findings have been positive for both human immune response and safety. The pharmaceutical company also shared that no subjects have withdrawn from the trials, nor have there been any serious adverse reactions in patients from the treatment thus far.
With new Covid-19 infections on the rise every day and the global tally of more than 50 million infections globally, hopes for a possible effective vaccine could not come sooner. – / ITGS
Follow us and like:
– Advertising –
[ad_2]
